FutureChem Co.Ltd (220100) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FutureChem Co.Ltd (220100) has a cash flow conversion efficiency ratio of 0.000x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩13.90 Million ≈ $9.42K USD) by net assets (₩52.79 Billion ≈ $35.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 220100 market cap overview for the company's overall valuation and market capitalisation.
FutureChem Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how FutureChem Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
FutureChem Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FutureChem Co.Ltd ranked by their cash flow conversion efficiency. Explore FutureChem Co.Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Multicampus Corporation
KQ:067280
|
0.001x |
|
Me2on Co. Ltd
KQ:201490
|
0.010x |
|
Fidelix Co. Ltd
KQ:032580
|
-0.050x |
|
CFSB Bancorp Inc
NASDAQ:CFSB
|
0.001x |
|
Syntec Construction Public Company Limited
BK:SYNTEC
|
-0.046x |
|
ASolid Technology Co Ltd
TWO:6485
|
0.027x |
|
Marvipol S.A.
WAR:MVP
|
0.008x |
|
GIIB Holdings Bhd
KLSE:7192
|
-0.621x |
Annual Cash Flow Conversion Efficiency for FutureChem Co.Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of FutureChem Co.Ltd from 2016 to 2025. View 220100 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩54.83 Billion ≈ $37.16 Million |
₩-2.43 Billion ≈ $-1.64 Million |
-0.044x | +24.98% |
| 2024-12-31 | ₩54.38 Billion ≈ $36.85 Million |
₩-3.21 Billion ≈ $-2.17 Million |
-0.059x | -1.38% |
| 2023-12-31 | ₩63.91 Billion ≈ $43.31 Million |
₩-3.72 Billion ≈ $-2.52 Million |
-0.058x | +46.36% |
| 2022-12-31 | ₩70.14 Billion ≈ $47.53 Million |
₩-7.61 Billion ≈ $-5.16 Million |
-0.109x | -94.08% |
| 2021-12-31 | ₩52.72 Billion ≈ $35.72 Million |
₩-2.95 Billion ≈ $-2.00 Million |
-0.056x | -6.51% |
| 2020-12-31 | ₩43.37 Billion ≈ $29.39 Million |
₩-2.28 Billion ≈ $-1.54 Million |
-0.052x | +78.37% |
| 2019-12-31 | ₩11.16 Billion ≈ $7.57 Million |
₩-2.71 Billion ≈ $-1.84 Million |
-0.243x | -19.64% |
| 2018-12-31 | ₩16.46 Billion ≈ $11.15 Million |
₩-3.34 Billion ≈ $-2.26 Million |
-0.203x | -94.51% |
| 2017-12-31 | ₩27.20 Billion ≈ $18.43 Million |
₩-2.84 Billion ≈ $-1.92 Million |
-0.104x | -49.37% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.37 Million |
₩-2.20 Billion ≈ $-1.49 Million |
-0.070x | -- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more